However, it is of note we demonstrate the ability to therapeutically target c-Myc, which regulates the expression of the β-catenin co-transcriptional factor LEF1, required for the retention of β-catenin in the nucleus, thereby potentiating activation of the WNT pathway that drives CRC [59]. The gene discussed is LEF1; the disease is colorectal carcinoma.